Acadia Healthcare plunges 30% from highs on weak FY2026 guidance
Behavioral health provider faces $25-30M headwind from NY Medicaid policy changes as CEO Osteen takes helm
Acadia Healthcare shares gave back nearly all of a 30% pre-earnings rally on Wednesday after the behavioral health provider announced full-year 2026 guidance that fell short of analyst expectations, reflecting mounting regulatory pressure from New York Medicaid policy changes.
The Franklin, Tennessee-based company projected adjusted earnings per share of $1.30 to $1.55 for fiscal 2026, well below the consensus estimate of $1.71. The guidance represents a significant decline from fiscal 2025 adjusted EPS of $2.00, underscoring the challenges facing newly appointed chief executive Debra K. Osteen, who returned to the role in January.
"The stock was priced for perfection after that 30% run-up," analysts noted. "When you combine guidance that's below consensus with these known Medicaid headwinds, investors are taking profits."
The fourth-quarter results showed revenue of $821.5 million, up 6.1% year-over-year, while adjusted EPS came in at $0.07 per share. However, investors focused squarely on the outlook for 2026, which includes a $25 million to $30 million headwind from New York's exclusion of out-of-state behavioral health referrals under Medicaid.
The company also faces a $15 million to $20 million reduction in existing Medicaid supplemental payments, net of provider taxes. These regulatory pressures compound existing challenges, including increased professional and general liability expenses that forced Acadia to lower its 2025 guidance in December.
Acadia operates inpatient psychiatric facilities, residential treatment centers, and outpatient behavioral health facilities across the United States and Puerto Rico. The New York market represents a significant portion of its patient base, making the state's Medicaid policy changes particularly impactful.
Osteen, who previously led Acadia as CEO from December 2018 to March 2022, reassumed the top position on January 20, 2026. Her return was intended to bring stability as the company navigates the complex Medicaid reimbursement environment and pursues a capital-intensive expansion strategy.
Upon her appointment, management reaffirmed full-year 2025 financial guidance, expressing confidence despite ongoing macroeconomic challenges. Investors are now watching closely to see how Osteen addresses operational inefficiencies, improves bed utilization, and stabilizes the company following recent issues.
"Debbie knows the business inside out, but she's walking into a perfect storm," said one healthcare analyst. "New York Medicaid restrictions, rising liability costs, and now guidance that suggests another down year. She needs to show a clear path to margin improvement."
Acadia's board has already taken steps to strengthen the balance sheet, reducing capital expenditures by $300 million for 2026 to enhance cash flow stability and manage debt. The company currently trades at approximately 0.5 times sales and 8.4 times EBITDA, below its 10-year medians and peer ratios, according to analyst research.
Analyst sentiment heading into earnings was cautious, with a consensus "Hold" rating and average price target of $18.62 as of February 18. The analyst breakdown showed an equal split between "Buy" and "Hold" ratings, with three "Sell" ratings. EPS estimates had experienced significant downward revisions, declining 92% over the 60 days prior to the earnings call, according to Guggenheim Securities analysis.
Some analysts had pointed to the potential for a "short squeeze" if results exceeded expectations or if 2026 guidance was stronger than anticipated. Instead, the tepid guidance sent shares lower, erasing much of the pre-earnings enthusiasm.
The stock has experienced extreme volatility, trading in a 52-week range of $11.43 to $42.85. Institutional ownership stands at 133.7%, indicating substantial short interest that could create volatility if Osteen's turnaround strategy gains traction.
For now, investors are focused on execution. Osteen's immediate priorities include mitigating the impact of New York Medicaid changes, improving operational efficiency, and restoring confidence in the company's earnings trajectory. With the stock trading at a significant discount to historical valuations, success in these areas could attract value investors, but the regulatory headwinds present a formidable challenge in the near term.